Our long-term therapy is based on a pancreatic proenzyme formulation that suppresses tumor recurrence and metastasis.
PRP, our lead candidate, controls cancer cell migration, inhibits tumor blood vessel formation and triggers the cell’s death.
Propanc Biopharma Initiates Development of Bio-Analytical Assay in Preparation for Human Trials
Propanc Biopharma Commences Drug Discovery Research Collaboration
80% of all cancers are solid tumors. We are initially targeting pancreatic, ovarian and colorectal tumors.
Aug 3, 2022
Stay informed about our latest news and updates